BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31693921)

  • 1. Immune activation, immune senescence and levels of Epstein Barr Virus in kidney transplant patients: Impact of mTOR inhibitors.
    Petrara MR; Serraino D; Di Bella C; Neri F; Del Bianco P; Brutti M; Carmona F; Ballin G; Zanini S; Rigotti P; Furian L; De Rossi A
    Cancer Lett; 2020 Jan; 469():323-331. PubMed ID: 31693921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder.
    Thieme CJ; Schulz M; Wehler P; Anft M; Amini L; Blàzquez-Navarro A; Stervbo U; Hecht J; Nienen M; Stittrich AB; Choi M; Zgoura P; Viebahn R; Schmueck-Henneresse M; Reinke P; Westhoff TH; Roch T; Babel N
    Kidney Int; 2022 Dec; 102(6):1392-1408. PubMed ID: 36103953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
    Merlino C; Cavallo R; Bergallo M; Giacchino F; Bollero C; Negro Ponzi A; Cavallo G
    New Microbiol; 2003 Apr; 26(2):141-9. PubMed ID: 12737195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
    Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
    Babel N; Gabdrakhmanova L; Hammer M; Rosenberger C; Oppert M; Volk HD; Reinke P
    Transpl Infect Dis; 2005; 7(3-4):133-6. PubMed ID: 16390402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission of Epstein-Barr virus-positive post-transplant lymphoproliferative disorder by conversion to everolimus in a kidney transplant recipient.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
    Transpl Infect Dis; 2019 Aug; 21(4):e13116. PubMed ID: 31102475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus, rapamycin, and host immune responses.
    Krams SM; Martinez OM
    Curr Opin Organ Transplant; 2008 Dec; 13(6):563-8. PubMed ID: 19060543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (EBV) viremia in EBV-seronegative kidney transplant recipients from EBV-seropositive donors: results of a pilot study.
    Schachtner T; Reinke P
    Transpl Infect Dis; 2016 Dec; 18(6):881-888. PubMed ID: 27632022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
    G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of mTOR and calcineurin inhibitors combined therapy in Epstein-Barr virus positive and negative Burkitt lymphoma cells.
    Wowro SJ; Schmitt KRL; Tong G; Berger F; Schubert S
    Int Immunopharmacol; 2016 Jan; 30():9-17. PubMed ID: 26613512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
    Martinez OM; Krams SM
    Transplantation; 2017 Sep; 101(9):2009-2016. PubMed ID: 28376031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
    Dolcetti R
    Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment.
    Petrara MR; Giunco S; Serraino D; Dolcetti R; De Rossi A
    Cancer Lett; 2015 Dec; 369(1):37-44. PubMed ID: 26279520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus load for early detection of lymphoproliferative disorder in pediatric renal transplant recipients.
    Ishihara M; Tanaka E; Sato T; Chikamoto H; Hisano M; Akioka Y; Dohno S; Maeda A; Hattori M; Wakiguchi H; Fujieda M
    Clin Nephrol; 2011 Jul; 76(1):40-8. PubMed ID: 21722604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
    San-Juan R; Manuel O; Hirsch HH; Fernández-Ruiz M; López-Medrano F; Comoli P; Caillard S; Grossi P; Aguado JM; ;
    Clin Microbiol Infect; 2015 Jun; 21(6):604.e1-9. PubMed ID: 25686696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
    Fellner MD; Durand KA; Solernou V; Bosaleh A; Balbarrey Z; García de Dávila MT; Rodríguez M; Irazu L; Alonio LV; Picconi MA
    Rev Argent Microbiol; 2016; 48(2):110-8. PubMed ID: 27157146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.